Role of ezetimibe in secondary cardiovascular prevention finally determined?
Lanzi, D.; Fumeaux, T.
Revue Medicale Suisse 11(496): 2257
2015
ISSN/ISBN: 1660-9379 PMID: 26742360 Document Number: 679274
Document emailed within 1 workday
Related Documents
Wander, G.S.; Hukkeri, M.Yunus.Khan.; Yalagudri, S.; Mahajan, B.; Panda, A.Toppo. 2018: Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease Journal of the Association of Physicians of India 66(3): 70-741999: Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases: The Role of the Cardiovascular Specialist Canadian Journal of Cardiology 15 Suppl G: 1g
Chopeĭ, I.V.; Rosul, M.M.; Hechko, M.M.; Chubirko, K.I.; Korabel'shchykova, M.O.; Ivan'o, N.V. 2014: Cardiovascular continuum: the role of the family doctor in prevention of cardiovascular diseases Wiadomosci Lekarskie 67(2 Pt 2): 243-247
Chazov, E.I. 2002: Problems in primary and secondary prevention of cardiovascular diseases Terapevticheskii Arkhiv 74(9): 5-8
Labresh, K.A.; Tyler, P.A. 2005: Linking the hospital and the office in cardiovascular secondary prevention American Family Physician 71(3): 430 432-3
García-Palmieri, M.R. 2000: Primary and secondary prevention of cardiovascular disease in the elderly Boletin de la Asociacion Medica de Puerto Rico 92(1-3): 3-8
Tkacheva, O.N.; Sharashkina, N.V. 2010: Possibilities of ramipril in primary and secondary prevention of cardiovascular diseases Kardiologiia 50(8): 63-66
Richard, J.L.; Delahaye, F. 1998: Cardiovascular prevention, primary or secondary, in high risk patients Archives des Maladies du Coeur et des Vaisseaux 91(12): 1495-1502
Schlierf, G. 1980: Primary and secondary prevention of cardiovascular diseases - metabolic aspects Verhandlungen der Deutschen Gesellschaft für Innere Medizin 86: 546-550
Brett, T.; McGuire, S.; Meade, B.; Leahy, J. 2006: Secondary prevention of cardiovascular disease--a possible model for Australian general practice Australian Family Physician 35(3): 157-159
Klomp, C.M.C.; ten Cate, H.; Stehouwer, C.D.A.; Schaper, N.C. 2009: Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events Nederlands Tijdschrift Voor Geneeskunde 153: A109
Pavić, J.; Zupanić, M.; Milanović, S.Musić.; Fister, K. 2009: Primary and secondary prevention of cardiovascular diseases embedded in the visiting nurse services: description of the intervention model Collegium Antropologicum 33 Suppl. 1: 81-86
Mayer, F.; Kirchmayer, U.; Di Martino, M.; Agabiti, N.; Fusco, D.; Davoli, M. 2015: Impact of a Decree on ACE inhibitors/ARBs in cardiovascular secondary prevention in the Lazio Region (Central Italy): a pre-post analysis Epidemiologia e Prevenzione 39(1): 19-27
Onder, L.; Nicolosi, G.Luigi. 2010: The primary role of cardiologists in cardiovascular prevention Giornale Italiano di Cardiologia 11(5 Suppl. 3): 131s-132s
Nightingale, A.; Marshall, A. 1998: Secondary prevention in acute myocardial infarction. Long term insulin treatment is important in secondary prevention in diabetic patients Bmj 317(7166): 1153
Metelitsa, V.I.; Ostrovskaia, T.P.; Duda, S.G.; Filatova, N.P.; Vygodin, V.A.; Mukhamedzhanova, G.F. 1994: The basic antihypertensive drugs for the long-term secondary prevention of cardiovascular diseases (the working group of the multicenter study Captopril and the Quality of Life) Terapevticheskii Arkhiv 66(9): 78-82
Giunta, S.; Piantanelli, L.; Basso, A.; Morresi, A.; Lanza, R.; Groppa, G.; Caruso, U.; Fiori, L. 1993: The role of medical counseling in secondary prevention of cancer in the elderly Tumori 79(5): 297-300
Demaurex, C.G.; Geyer-Smadja, I.; Ansermet, F. 2001: Role of secondary prevention in a specialized consultation for sexual abuse and negligence Revue Medicale de la Suisse Romande 121(7): 507-512
Hu, F.B.. 2001: The role of n-3 polyunsaturated fatty acids in the prevention and treatment of cardiovascular disease Drugs of Today 37(1): 49-56
Wagner, M.; Goetghebeur, M.; Merikle, E.; Pandya, A.; Chu, P.; Taylor, D.C.A. 2009: Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada Canadian Journal of Clinical Pharmacology 16(2): E331-E345